Caroline Stridsman

Caroline Stridsman

Auto-generated profile, based on publicly available information

Caroline Stridsman

Department of public health and clinical medicine, The OLIN unit, Umeå University, Umeå, Sweden

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LVLowie Vanfleteren
Lowie Vanfleteren
ALAnne Lindberg
Anne Lindberg
CZCaddie Zhou
Caddie Zhou
FNFredrik Nyberg
Fredrik Nyberg
CSCaroline Stridsman
Caroline Stridsman
Rationale: Risk stratification of patients according to chronic obstructive pulmonary disease severity is clinically important and forms the basis of therapeutic recommendations. No studies have examined the association for Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A and group B patients with (A1 and B1, respectively) and without (A0 and B0, respectively) an exacerbation in the past year with future exacerbations, hospitalizations, and mortality in perspective with the new GOLD ABE classification. Objectives: The aim was to examine the association between GOLD A0, A1, B0, B1, and E patients and future exacerbations, respiratory and cardiovascular hospitalizations, and mortality. Methods: In this nationwide cohort study, we identified patients with a diagnosis of chronic obstructive pulmonary disease, aged ≥30 years, and registered in the Swedish National Airway Register between January 2017 and August 2020. Patients were stratified in GOLD groups A0, A1, B0, B1, and E and were followed until January 2021 for exacerbations, hospitalizations, and mortality in national registries. Measurements and Main Results: The 45,350 eligible patients included 25% A0, 4% A1, 44% B0, 10% B1, and 17% E. Moderate exacerbations, all-cause and respiratory hospitalizations, and all-cause and respiratory mortality increased by GOLD group A0-A1-B0-B1-E, except for moderate exacerbations, which were higher in A1 than in B0. Group B1 had a substantially higher hazard ratio for future exacerbation (2.56; 95% confidence interval [95% CI] 2.40–2.74), all-cause hospitalization (1.28; 1.21–1.35), and respiratory hospitalization (1.44; 1.27–1.62), but not all-cause (1.04; 0.91–1.18) or respiratory (1.13; 0.79–1.64) mortality than group B0. The exacerbation rate for group B1 was 0.6 events per patient-year versus 0.2 for group B0 (rate ratio, 2.55; 95% CI, 2.36–2.76). Results were similar for group A1 versus group A0. Conclusions: Stratification of GOLD A and B patients with one or no exacerbation in the past year provides valuable information on future risk, which should influence treatment recommendations for preventive strategies.

28 August 2015 in Tobacco Induced Diseases
Verified
Journal Article
Open access
ALAnne Lindberg
Anne Lindberg
BNBenjamin Niska
Benjamin Niska
CSCaroline Stridsman
Caroline Stridsman
BEBritt-Marie Eklund
Britt-Marie Eklund
BEBerne Eriksson
Berne Eriksson
LHLinnea Hedman
Linnea Hedman
Background: Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD), and smoking cessation is the only intervention that slows disease progression. It is important to know whether current factors related to smoking and smoking cessation are different among subjects with...

1 February 2020 in Respiratory Medicine
Verified
Journal Article
Closed access
SJSven-Arne Jansson
Sven-Arne Jansson
HBHelena Backman
Helena Backman
MAMaria Andersson
Maria Andersson
GTGunilla Telg
Gunilla Telg
ALAnne Lindberg
Anne Lindberg
EREva Rönmark
Eva Rönmark

1 January 2020 in European Clinical Respiratory Journal
Verified
Journal Article
Open access
CSC Stridsman
C Stridsman
JKJr Konradsen
Jr Konradsen
LVLowie Vanfleteren
Lowie Vanfleteren
CPC Pedroletti
C Pedroletti
JBJ Binnmyr
J Binnmyr
AEA Ekberg-Jansson
A Ekberg-Jansson
The Swedish National Airway Register (SNAR) was initiated in 2013 to ensure and improve the quality of care for patients with asthma and COPD.To describe the development and design of SNAR, and to ...

26 April 2017 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
CSCaroline Stridsman
Caroline Stridsman
HBHelena Backman
Helena Backman
BEBritt‐Marie Eklund
Britt‐Marie Eklund
EREva Rönmark
Eva Rönmark
LHLinnea Hedman
Linnea Hedman

1 March 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
HBHelena Backman
Helena Backman
ALAnne Lindberg
Anne Lindberg
LHLinnea Hedman
Linnea Hedman
CSCaroline Stridsman
Caroline Stridsman
SJSven-Arne Jansson
Sven-Arne Jansson
EREva Rönmark
Eva Rönmark
The relationship between lung function decline and eosinophils and neutrophils has important therapeutic implications among asthmatics, but it has rarely been studied in large cohort studies. The aim is to study the relationship between blood eosinophils and neutrophils and FEV1 decline in a long-term follow-up of a population-based adult asthma cohort. In 2012-2014, an adult asthma cohort was invited to a follow-up including spirometry, blood sampling, and structured interviews, and n = 892 participated (55% women, mean age 59 y, 32-92 y). Blood eosinophils, neutrophils and FEV 1 decline were analyzed both as continuous variables and divided into categories with different cut-offs. Regression models adjusted for smoking, exposure to vapors, gas, dust, or fumes (VGDF), use of inhaled and oral corticosteroids, and other possible confounders were utilized to analyze the relationship between eosinophils and neutrophils at follow-up and FEV1 decline. The mean follow-up time was 18 years, and the mean FEV 1 decline was 27 ml/year. The annual FEV1 decline was related to higher levels of both blood eosinophils and neutrophils at follow-up, but only the association with eosinophils remained when adjusted for confounders. Further, the association between FEV1 decline and eosinophils was stronger among those using ICS. With EOS <0.3 × 109/L as reference, a more rapid decline in FEV1 was independently related to EOS ≥0.4 × 109/L in adjusted analyses. Besides emphasizing the importance of smoking cessation and reduction of other harmful exposures, our real-world results indicate that there is an independent relationship between blood eosinophils and FEV1 decline among adults with asthma.